Danish Marine and Shipping Stock News

Novo Nordisk (CPSE:NOVO B) has expanded its partnership with Aspect Biosystems, giving Aspect new rights related to cellular diabetes medicines. Responsibility for certain development and commercialization activities in curative diabetes therapies has shifted within the collaboration. The company has also been named as a defendant in a federal antitrust lawsuit focused on competition in the GLP-1 medication market. Novo Nordisk, known for its diabetes and obesity treatments, is now pushing...

A.P. Møller Mærsk (CPSE:MAERSK B) has initiated the second phase of a multi billion DKK share buy back program. The program is designed to repurchase a substantial portion of the company’s own shares over a defined period. This step affects the capital structure and has implications for existing and potential shareholders. A.P. Møller Mærsk operates across container shipping, logistics and related services, so its decisions around capital allocation draw close attention from investors. The...

DSV recently broke ground on a new 950,000-square-foot regional headquarters and logistics hub in Mesa, Arizona, a US$14.5 million facility that will integrate air, sea, road, and contract logistics services for the southwestern United States. The site is set to become a central hub serving major clients such as TSMC and Intel, reinforcing DSV’s role in supporting Arizona’s growing semiconductor and technology supply chains. We’ll now look at how this Mesa expansion, particularly its role...

If you are wondering whether Genmab shares still offer value after a strong run, this article walks through what the current price might be implying about the company. The stock is up 5.5% year to date and 40.1% over the last year. However, the 3 year and 5 year returns of 20.1% and 15.0% declines show a more mixed picture. Recent moves in Genmab's share price have come alongside ongoing attention on large biotech names and investor interest in companies with established pipelines, which...

Jyske Bank A/S recently raised its 2025 earnings guidance, now expecting a net profit of DKK 5.40 billion and earnings per share of DKK 85, up from an earlier DKK 4.90–5.30 billion range and DKK 77–84 per share, citing broad business momentum and supportive financial markets. The upgraded outlook, combined with an ongoing share repurchase programme of up to DKK 2.25 billion that has lifted treasury holdings to 5.20% of share capital, highlights management's confidence in the bank's current...

Tryg (CPSE:TRYG) has attracted fresh attention after reporting stronger fourth quarter earnings, announcing a DKK 1b share buyback and lifting its ordinary dividend, with customer satisfaction and Norwegian profitability also moving in a positive direction. See our latest analysis for Tryg. The recent Q4 beat, share buyback launch and higher ordinary dividend come after a year in which the share price has been relatively muted. The 1 year total shareholder return of 15.35% points to momentum...

ISS A/S previously announced a new share buyback programme running from 20 February 2025 to 13 February 2026, with up to DKK 3,000 million earmarked to return excess cash to shareholders and support share-based incentive plans. Following recent transactions, ISS A/S holds 13,393,562 treasury shares, representing 7.69% of its share capital, highlighting the growing role of buybacks in its capital allocation approach. We will now examine how this sizeable DKK 3,000 million buyback shapes ISS...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Novo Nordisk (CPSE:NOVO B) received FDA approval for Wegovy as the first oral GLP-1 weight-loss medication and is launching the pill for commercial use. The company expanded its partnership with Aspect Biosystems to develop allogeneic cell therapies aimed at treating diabetes. Both moves extend Novo Nordisk's presence in obesity care and diabetes therapies beyond injectable drugs. Novo Nordisk, long known for its insulin and GLP-1 injection portfolio, is now adding an oral GLP-1 weight-loss...

If you are wondering whether Novozymes is attractively priced or looking stretched at today’s levels, you are in the right place for a clear, valuation focused rundown of the stock. The share price last closed at DKK 412.0, with returns of 2.6% over the past year and 25.2% over three years. Shorter term moves include a 2.4% decline over 7 days, a 1.8% gain over 30 days, and a 3.8% return year to date. Recent news coverage around Novozymes has largely centered on its role in specialty enzymes...

Ørsted has completed installation of the final wind turbine at its 920 MW Greater Changhua 2b and 4 offshore wind farms in Taiwan, a key milestone for the Asia-Pacific offshore wind industry. The project is the first in the region to supply renewable electricity under a corporate power purchase agreement, with full commercial operations expected in Q3 2026. We will now examine how completing the final turbine installation and progressing toward commercial operations shapes Ørsted’s broader...

Key Insights Per Aarsleff Holding's estimated fair value is kr.860 based on 2 Stage Free Cash Flow to Equity Current...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Demant fair value estimate is kr.302 Current share price of...

Why Pandora’s 2025 Guidance Has Grabbed Investor Attention Pandora (CPSE:PNDORA) has put fresh numbers on the table, guiding for a Q4 2025 EBIT margin of around 33.5% and full year EBIT of about DKK 7.8b, with a group margin near 24%. This earnings outlook, presented on the Q4 2025 guidance call, gives readers clearer visibility on profitability expectations at a time when the share price has faced pressure over the past year. See our latest analysis for Pandora. The guidance comes after a...

Amylyx Pharmaceuticals’ decision to advance AMX0318, a GLP-1 receptor antagonist discovered with Gubra (CPSE:GUBRA), into development puts fresh attention on Gubra’s partnership model and its potential milestone and royalty stream. See our latest analysis for Gubra. The Amylyx milestone news comes after a mixed period for Gubra, with a 1 day share price return of 0.41% and a 90 day share price return of 4.96%. This is set against a year to date share price return of a 16.74% decline and a 1...

FLSmidth (CPSE:FLS) has been in focus after launching a share buy-back programme of up to DKK 1.4b, authorising the repurchase of as many as 4,600,000 shares, which is around 8% of its share capital. See our latest analysis for FLSmidth. The buy-back arrives after a strong run, with the 1-month share price return of 21.08% and year-to-date share price return of 18.39% adding to a 1-year total shareholder return of 48.45%. This indicates that momentum has been building over both shorter and...

Alm. Brand A/S has reported that its 2025 insurance service result reached DKK 1.91 billion, above its stated financial target, and the Board has proposed an ordinary dividend of DKK 0.66 per share alongside plans for a new DKK 1.5 billion share buyback programme in 2026. This combination of exceeding internal performance goals and committing around DKK 2.4 billion to dividends and repurchases highlights a strong focus on shareholder returns. With Alm. Brand pairing a solid 2025 insurance...

NKT (CPSE:NKT) is back in focus after confirming final contracts with SSEN Transmission for two 525 kV HVDC cable projects in Scotland, adding about €2b of turnkey work to its high voltage backlog. See our latest analysis for NKT. The latest HVDC contract win and recent product launch around dry type high voltage terminations come against a backdrop of a 10.63% 90 day share price return and a 5 year total shareholder return of 236.01%. This suggests momentum has been building over time...

Recent performance snapshot A.P. Møller - Mærsk (CPSE:MAERSK B) has seen mixed short term returns, with a gain of about 1.1% over the past day, a 5.5% decline over the past week, and a 2.9% rise over the past month. Looking a bit further back, the stock shows a 15.4% return over the past 3 months and around 0.6% year to date. The 1 year total return stands at about 56.0%. See our latest analysis for A.P. Møller - Mærsk. At a share price of DKK 14,860, A.P. Møller - Mærsk combines a recent dip...

Tryg (CPH:TRYG) has had a rough month with its share price down 1.6%. However, the company's fundamentals look pretty...

One thing we could say about the covering analyst on cBrain A/S ( CPH:CBRAIN ) - they aren't optimistic, having just...

RIAS A/S ( CPH:RIAS B ) has announced that on 26th of January, it will be paying a dividend ofDKK26.00, which a...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

To the annoyance of some shareholders, Pandora A/S ( CPH:PNDORA ) shares are down a considerable 26% in the last month...